Our distinguished Medical Advisory Board provides strategic counsel on research breakthroughs and patient programs.
Dr. Demetri feels that his particular strength is new drug development based on rational scientific targets.
Dr. Forscher’s particular strength lies in utilizing nonadjuvant chemotherapy to gain a better understanding of the response of particular sarcomas to treatment. Dr. Forscher limited his practice to the study and treatment of sarcomas and has more than twenty years of experience in the field. His referral base is nationwide.
Dr. Pollock became Chairman of the Department of Surgical Oncology in 1993, was promoted to Professor in 1995, and became Head of the Division of Surgery at The University of Texas M. D. Anderson Cancer Center in 1997. In 2013, Dr. Pollock joined The Ohio State University Wexner Medical Center College of Medicine Department of Surgery as the Director of the Division of Surgical Oncology and the Chief of Surgical Services of the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James)
He received his medical education at Universiteit Van Amsterdam (1986) Netherlands. He has been Board Certification in Anatomic Pathology by the American Board of Pathology since 1993. He completed his residency at Stanford University School of Medicine and Fellowship at Stanford Hospital and Clinics in 1994.
Dr. Trent’s interests are in the clinical and translational research of sarcomas, direct care of sarcoma patients, and education about sarcoma. As Associate Director for Clinical Research, his goal is to develop clinical trials that provide molecular testing of a patient’s tumor and molecularly targeted therapy to cancer patients of South Florida and beyond.
The major focus of his clinical, educational and research efforts are with gastrointestinal stromal tumors (GIST) and all other sarcomas including myxofibrosarcoma, leiomyosarcoma, liposarcoma, chondrosarcoma, angiosarcoma, synovial sarcoma, pigmented villonodular synovitis, dermatofibrosarcoma protuberans perivascular endothelial cell sarcoma (PEComa), angiomyolipoma, alveolar soft-parts sarcoma, and rhabdomyosarcoma. The major efforts of Dr. Trent’s research focus on understanding the mechanisms of action and resistance of imatinib in GIST and other sarcomas while striving toward improved therapeutic options. His work involves the use of novel preoperative/postoperative clinical trials, prospectively acquired tumor tissue, cell lines, archival tissue, as well as collaborations with disciplines such as the genomics facility, surgical oncology, pathology, radiology and interventional radiology.
He is on currently staff at City of Hope (Duarte campus) and Huntington Memorial Hospital (Pasadena).